Glutathione S-transferase and drug resistance.

L. A. Cazenave, J. A. Moscow, C. E. Myers, K. H. Cowan

Research output: Contribution to journalReview article

21 Citations (Scopus)

Abstract

GST isozymes are an important part of the normal cellular defense against toxic xenobiotics and carcinogens. These multifunctional proteins can interact with a broad range of substrates in a variety of ways. In particular, GSTs have been implicated in the detoxication of many antineoplastic agents. Elevated levels of certain GST isozymes have been associated with malignant transformation and with experimental drug resistance. Although the role of GST in antineoplastic drug resistance is unclear, recent studies have shown increased activity of GST in many human tumors relative to normal tissues. These findings raise the possibility that the presence of certain GST isozymes may be a marker for malignant transformation in some human tumors, and that GSTs may play a role in de novo and acquired drug resistance. Identifying the factors which regulate the expression of these drug-metabolizing enzymes as well as agents which inhibit their activities may provide new insights into the therapy of tumors clinically refractory to chemotherapy.

Original languageEnglish (US)
Pages (from-to)171-187
Number of pages17
JournalCancer treatment and research
Volume48
StatePublished - Dec 1 1989

Fingerprint

Glutathione Transferase
Drug Resistance
Isoenzymes
Neoplasm Drug Resistance
Neoplasms
Poisons
Xenobiotics
Carcinogens
Antineoplastic Agents
Drug Therapy
Enzymes
Pharmaceutical Preparations
Proteins
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Cazenave, L. A., Moscow, J. A., Myers, C. E., & Cowan, K. H. (1989). Glutathione S-transferase and drug resistance. Cancer treatment and research, 48, 171-187.

Glutathione S-transferase and drug resistance. / Cazenave, L. A.; Moscow, J. A.; Myers, C. E.; Cowan, K. H.

In: Cancer treatment and research, Vol. 48, 01.12.1989, p. 171-187.

Research output: Contribution to journalReview article

Cazenave, LA, Moscow, JA, Myers, CE & Cowan, KH 1989, 'Glutathione S-transferase and drug resistance.', Cancer treatment and research, vol. 48, pp. 171-187.
Cazenave LA, Moscow JA, Myers CE, Cowan KH. Glutathione S-transferase and drug resistance. Cancer treatment and research. 1989 Dec 1;48:171-187.
Cazenave, L. A. ; Moscow, J. A. ; Myers, C. E. ; Cowan, K. H. / Glutathione S-transferase and drug resistance. In: Cancer treatment and research. 1989 ; Vol. 48. pp. 171-187.
@article{c1090ee6ab5f4cb7aa9d8822fa6fd6b0,
title = "Glutathione S-transferase and drug resistance.",
abstract = "GST isozymes are an important part of the normal cellular defense against toxic xenobiotics and carcinogens. These multifunctional proteins can interact with a broad range of substrates in a variety of ways. In particular, GSTs have been implicated in the detoxication of many antineoplastic agents. Elevated levels of certain GST isozymes have been associated with malignant transformation and with experimental drug resistance. Although the role of GST in antineoplastic drug resistance is unclear, recent studies have shown increased activity of GST in many human tumors relative to normal tissues. These findings raise the possibility that the presence of certain GST isozymes may be a marker for malignant transformation in some human tumors, and that GSTs may play a role in de novo and acquired drug resistance. Identifying the factors which regulate the expression of these drug-metabolizing enzymes as well as agents which inhibit their activities may provide new insights into the therapy of tumors clinically refractory to chemotherapy.",
author = "Cazenave, {L. A.} and Moscow, {J. A.} and Myers, {C. E.} and Cowan, {K. H.}",
year = "1989",
month = "12",
day = "1",
language = "English (US)",
volume = "48",
pages = "171--187",
journal = "Cancer Treatment and Research",
issn = "0927-3042",
publisher = "Springer Netherlands",

}

TY - JOUR

T1 - Glutathione S-transferase and drug resistance.

AU - Cazenave, L. A.

AU - Moscow, J. A.

AU - Myers, C. E.

AU - Cowan, K. H.

PY - 1989/12/1

Y1 - 1989/12/1

N2 - GST isozymes are an important part of the normal cellular defense against toxic xenobiotics and carcinogens. These multifunctional proteins can interact with a broad range of substrates in a variety of ways. In particular, GSTs have been implicated in the detoxication of many antineoplastic agents. Elevated levels of certain GST isozymes have been associated with malignant transformation and with experimental drug resistance. Although the role of GST in antineoplastic drug resistance is unclear, recent studies have shown increased activity of GST in many human tumors relative to normal tissues. These findings raise the possibility that the presence of certain GST isozymes may be a marker for malignant transformation in some human tumors, and that GSTs may play a role in de novo and acquired drug resistance. Identifying the factors which regulate the expression of these drug-metabolizing enzymes as well as agents which inhibit their activities may provide new insights into the therapy of tumors clinically refractory to chemotherapy.

AB - GST isozymes are an important part of the normal cellular defense against toxic xenobiotics and carcinogens. These multifunctional proteins can interact with a broad range of substrates in a variety of ways. In particular, GSTs have been implicated in the detoxication of many antineoplastic agents. Elevated levels of certain GST isozymes have been associated with malignant transformation and with experimental drug resistance. Although the role of GST in antineoplastic drug resistance is unclear, recent studies have shown increased activity of GST in many human tumors relative to normal tissues. These findings raise the possibility that the presence of certain GST isozymes may be a marker for malignant transformation in some human tumors, and that GSTs may play a role in de novo and acquired drug resistance. Identifying the factors which regulate the expression of these drug-metabolizing enzymes as well as agents which inhibit their activities may provide new insights into the therapy of tumors clinically refractory to chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0024780543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024780543&partnerID=8YFLogxK

M3 - Review article

C2 - 2577137

AN - SCOPUS:0024780543

VL - 48

SP - 171

EP - 187

JO - Cancer Treatment and Research

JF - Cancer Treatment and Research

SN - 0927-3042

ER -